FR04C0024I1 - - Google Patents
Info
- Publication number
- FR04C0024I1 FR04C0024I1 FR04C0024C FR04C0024I1 FR 04C0024 I1 FR04C0024 I1 FR 04C0024I1 FR 04C0024 C FR04C0024 C FR 04C0024C FR 04C0024 I1 FR04C0024 I1 FR 04C0024I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9203594A SE9203594D0 (sv) | 1992-11-30 | 1992-11-30 | Laekemedel i dispersa system |
| PCT/SE1993/001029 WO1994012153A1 (en) | 1992-11-30 | 1993-11-29 | A pharmaceutical formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR04C0024I1 true FR04C0024I1 (de) | 2004-03-12 |
| FR04C0024I2 FR04C0024I2 (de) | 2010-12-31 |
Family
ID=20387973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR04C0024C Active FR04C0024I2 (de) | 1992-11-30 | 2004-10-22 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5635213A (de) |
| EP (1) | EP0670713B3 (de) |
| JP (1) | JP3661703B2 (de) |
| AT (1) | ATE184191T3 (de) |
| AU (1) | AU688290B2 (de) |
| CA (1) | CA2150464C (de) |
| DE (2) | DE69326350T3 (de) |
| DK (1) | DK0670713T3 (de) |
| ES (1) | ES2137350T7 (de) |
| FR (1) | FR04C0024I2 (de) |
| GR (1) | GR3031988T3 (de) |
| NL (1) | NL300169I1 (de) |
| NZ (1) | NZ258276A (de) |
| SE (1) | SE9203594D0 (de) |
| WO (1) | WO1994012153A1 (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
| US7919109B2 (en) * | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
| JP4653893B2 (ja) * | 2000-01-27 | 2011-03-16 | 純一 須藤 | 二層型経皮吸収製剤 |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| US7855195B2 (en) * | 2003-12-02 | 2010-12-21 | Pharmaneuroboost N.V. | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US20050119249A1 (en) * | 2003-12-02 | 2005-06-02 | Erik Buntinx | Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US7884096B2 (en) * | 2003-12-02 | 2011-02-08 | Pharmaneuroboost N.V. | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US8304431B2 (en) * | 2003-12-02 | 2012-11-06 | Pharmaneuroboost N.V. | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| CN101453982B (zh) | 2006-05-30 | 2011-05-04 | 精达制药公司 | 两件式内部通道渗透递送系统流动调节器 |
| RU2484815C2 (ru) * | 2006-05-31 | 2013-06-20 | Зольвай Фармасьютиклз Гмбх | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа |
| WO2008021133A2 (en) | 2006-08-09 | 2008-02-21 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
| EP2157967B1 (de) | 2007-04-23 | 2013-01-16 | Intarcia Therapeutics, Inc | Suspensionsformulierungen insulinotroper peptide und ihre verwendung |
| US8968786B2 (en) | 2007-06-22 | 2015-03-03 | Board Of Regents, The University Of Texas System | Formation of stable submicron peptide or protein particles by thin film freezing |
| EP2240155B1 (de) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe |
| WO2010056657A2 (en) | 2008-11-16 | 2010-05-20 | Board Of Regents, The Univesity Of Texas System | Low viscosity highly concentrated suspensions |
| CN104323981B (zh) | 2009-09-28 | 2019-03-12 | 精达制药公司 | 基本稳态药物递送的快速建立和/或终止 |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| US10335540B2 (en) | 2012-04-17 | 2019-07-02 | Micrel Medical Devices S.A. | Pharmaceutical blend infusion thereof and Parkinson's disease monitoring system |
| WO2016036308A1 (en) | 2014-09-04 | 2016-03-10 | Lobsor Pharmaceuticals Aktiebolag | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| EP3209302B1 (de) | 2014-10-21 | 2019-04-24 | AbbVie Inc. | Carbidopa und l-dopa prodrugs sowie ihre verwendung zur behandlung von parkinson krankheit |
| MA41377A (fr) * | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| KR20180004756A (ko) | 2015-05-06 | 2018-01-12 | 신애질 코포레이션 | 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법 |
| WO2016196851A2 (en) | 2015-06-03 | 2016-12-08 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
| WO2017039525A1 (en) | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| MX2018014016A (es) | 2016-05-16 | 2019-08-01 | Intarcia Therapeutics Inc | Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos. |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| BR112019001082A2 (pt) * | 2016-07-20 | 2019-04-30 | Abbvie Inc. | gel intestinal de levodopa e carbidopa e métodos de uso |
| CN110225762A (zh) | 2017-01-03 | 2019-09-10 | 因塔西亚制药公司 | 包括glp-1受体激动剂的连续施用和药物的共同施用的方法 |
| WO2019166322A1 (en) | 2018-03-02 | 2019-09-06 | Chiesi Farmaceutici S.P.A. | A pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa |
| IL277553B1 (en) | 2018-03-23 | 2024-07-01 | Lobsor Pharmaceuticals Ab | Preparations for the treatment of neurodegenerative diseases by continuous administration |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5831210B2 (ja) * | 1973-04-09 | 1983-07-05 | 武田薬品工業株式会社 | アンテイナスイセイケンダクエキノセイゾウホウ |
| DE2714065A1 (de) * | 1977-03-30 | 1978-10-12 | Boehringer Mannheim Gmbh | Instillationszubereitung |
| US4356824A (en) * | 1980-07-30 | 1982-11-02 | Vazquez Richard M | Multiple lumen gastrostomy tube |
| CH652025A5 (de) * | 1981-09-14 | 1985-10-31 | Hoffmann La Roche | Pharmazeutisches praeparat. |
| US4916151A (en) * | 1985-12-05 | 1990-04-10 | Merrell Dow Pharmaceuticals Inc. | Method of treating parkinson's syndrome |
| SE457326B (sv) * | 1986-02-14 | 1988-12-19 | Lejus Medical Ab | Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa |
| ATE76747T1 (de) * | 1986-06-10 | 1992-06-15 | Chiesi Farma Spa | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
| US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| GB8720600D0 (en) * | 1987-09-02 | 1987-10-07 | Saad Al Damluji | Pharmaceutical compositions |
| US4863962A (en) * | 1988-03-02 | 1989-09-05 | Fidia-Georgetown Institute For The Neurosciences | D-DOPA, pharmaceutically acceptable salts thereof, and methods of treating Parkinson's disease |
| US5326572A (en) * | 1989-03-23 | 1994-07-05 | Fmc Corporation | Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions |
| US5266332A (en) * | 1991-12-06 | 1993-11-30 | Alza Corporation | Method for administering anti-Parkinson drug |
| US5354885A (en) * | 1992-12-24 | 1994-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Process for preparing ethyl ester of L-DOPA |
-
1992
- 1992-11-30 SE SE9203594A patent/SE9203594D0/xx unknown
-
1993
- 1993-11-29 ES ES94901148.0T patent/ES2137350T7/es active Active
- 1993-11-29 WO PCT/SE1993/001029 patent/WO1994012153A1/en active IP Right Grant
- 1993-11-29 NZ NZ258276A patent/NZ258276A/en not_active IP Right Cessation
- 1993-11-29 AT AT94901148T patent/ATE184191T3/de unknown
- 1993-11-29 US US08/446,799 patent/US5635213A/en not_active Expired - Lifetime
- 1993-11-29 EP EP94901148.0A patent/EP0670713B3/de not_active Expired - Lifetime
- 1993-11-29 CA CA002150464A patent/CA2150464C/en not_active Expired - Lifetime
- 1993-11-29 DE DE69326350.4T patent/DE69326350T3/de not_active Expired - Lifetime
- 1993-11-29 DE DE200512000021 patent/DE122005000021I1/de active Pending
- 1993-11-29 AU AU55836/94A patent/AU688290B2/en not_active Expired
- 1993-11-29 DK DK94901148T patent/DK0670713T3/da active
- 1993-11-29 JP JP51306094A patent/JP3661703B2/ja not_active Expired - Lifetime
-
1999
- 1999-11-30 GR GR990403081T patent/GR3031988T3/el unknown
-
2004
- 2004-10-22 FR FR04C0024C patent/FR04C0024I2/fr active Active
-
2005
- 2005-01-03 NL NL300169C patent/NL300169I1/nl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NL300169I1 (nl) | 2005-03-01 |
| AU5583694A (en) | 1994-06-22 |
| JP3661703B2 (ja) | 2005-06-22 |
| US5635213A (en) | 1997-06-03 |
| GR3031988T3 (en) | 2000-03-31 |
| ATE184191T3 (de) | 1999-09-15 |
| CA2150464A1 (en) | 1994-06-09 |
| ES2137350T7 (es) | 2017-11-13 |
| WO1994012153A1 (en) | 1994-06-09 |
| AU688290B2 (en) | 1998-03-12 |
| EP0670713B1 (de) | 1999-09-08 |
| ES2137350T3 (es) | 1999-12-16 |
| DE69326350T3 (de) | 2018-01-11 |
| DK0670713T3 (da) | 2000-03-20 |
| SE9203594D0 (sv) | 1992-11-30 |
| FR04C0024I2 (de) | 2010-12-31 |
| DE69326350T2 (de) | 2000-01-27 |
| DE122005000021I1 (de) | 2006-02-23 |
| DE69326350D1 (de) | 1999-10-14 |
| JPH08504764A (ja) | 1996-05-21 |
| NZ258276A (en) | 1996-09-25 |
| EP0670713A1 (de) | 1995-09-13 |
| CA2150464C (en) | 2002-02-05 |
| EP0670713B3 (de) | 2016-10-05 |